Janssen Secures Temporary Block Against Arthritis Biosimilar
A Delaware federal judge has blocked Accord BioPharma from manufacturing a biosimilar version of Janssen's arthritis treatment Simponi while the Johnson & Johnson unit's patent lawsuit plays out....To view the full article, register now.
Already a subscriber? Click here to view full article